Compare GWH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | SNTI |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 29.8M |
| IPO Year | N/A | 2021 |
| Metric | GWH | SNTI |
|---|---|---|
| Price | $0.86 | $1.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.25 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 764.2K | 163.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.77 |
| 52 Week High | $13.87 | $2.88 |
| Indicator | GWH | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 57.03 |
| Support Level | $0.73 | $0.88 |
| Resistance Level | $1.15 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 37.47 | 64.66 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).